T. Rowe Price Associates
VNDA icon

T. Rowe Price Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

T. Rowe Price Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Hold
41,820
– – ﹤0.01% 2910
2026
Q1 		$289K Buy
41,820
+6,537
+19% +$50.4K ﹤0.01% 2699
2025
Q4 		$312K Buy
35,283
+6,027
+21% +$33.2K ﹤0.01% 2626
2025
Q3 		$146K Buy
29,256
+2,491
+9% +$11.5K ﹤0.01% 2860
2025
Q2 		$127K Hold
26,765
– – ﹤0.01% 2847
2025
Q1 		$123K Buy
26,765
+4,500
+20% +$21K ﹤0.01% 2782
2024
Q4 		$107K Buy
22,265
+3,370
+18% +$16.2K ﹤0.01% 2823
2024
Q3 		$89K Buy
18,895
+1,865
+11% +$10K ﹤0.01% 2843
2024
Q2 		$97K Buy
17,030
+1,206
+8% +$6.23K ﹤0.01% 2764
2024
Q1 		$66K Buy
15,824
+2,425
+18% +$9.71K ﹤0.01% 2837
2023
Q4 		$57K Buy
13,399
+1,244
+10% +$5.02K ﹤0.01% 2791
2023
Q3 		$53K Buy
12,155
+726
+6% +$4.03K ﹤0.01% 2771
2023
Q2 		$76K Buy
11,429
+1,049
+10% +$6.72K ﹤0.01% 2740
2023
Q1 		$71K Buy
+10,380
New +$73K ﹤0.01% 2742
2015
Q2 		– Sell
-365,628
Closed -$3.4M – 2560
2015
Q1 		$3.4M Sell
365,628
-4,209,593
-92% -$47.6M ﹤0.01% 1524
2014
Q4 		$65.5M Buy
4,575,221
+470,700
+11% +$5.57M 0.01% 744
2014
Q3 		$42.6M Buy
4,104,521
+677,730
+20% +$8.88M 0.01% 889
2014
Q2 		$55.4M Buy
3,426,791
+1,674,910
+96% +$22.3M 0.01% 831
2014
Q1 		$28.5M Buy
1,751,881
+543,480
+45% +$7.73M 0.01% 1017
2013
Q4 		$15M Buy
1,208,401
+1,185,201
+5,109% +$11.9M ﹤0.01% 1175
2013
Q3 		$255K Sell
23,200
-5,100
-18% -$54.5K ﹤0.01% 2174
2013
Q2 		$229K Buy
+28,300
New +$191K ﹤0.01% 2165

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's VNDA Position: Q2 2026 in Review

T. Rowe Price Associates held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 41,820 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #2910.

T. Rowe Price Associates first reported a position in VNDA in Q2 2013 and has held it in 22 quarters since. The position peaked at $65.5M in Q4 2014. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • T. Rowe Price Associates held 41,820 shares of Vanda Pharmaceuticals worth $256K as of Q2 2026.
  • T. Rowe Price Associates left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2910 holding.
  • T. Rowe Price Associates first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Vanda Pharmaceuticals position peaked at $65.5M in Q4 2014.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.